Semaglutide Side Effects: FDA-Labelled Risks Explained
Semaglutide is the GLP-1 receptor agonist sold as Ozempic (type 2 diabetes), Wegovy (weight management), and Rybelsus (oral). The most common side effects are gastrointestinal, nausea, vomiting, diarrhoea, constipation, abdominal pain. The most serious are pancreatitis, gallbladder disease, kidney injury, severe hypoglycaemia with insulin, and a boxed warning about thyroid C-cell tumours.
Semaglutide (Ozempic, Wegovy, Rybelsus) (Semaglutide) is approved as a Glucagon-like peptide-1 (GLP-1) receptor agonist. Most common side effects are gastrointestinal (nausea, vomiting, diarrhoea, constipation). Serious risks include pancreatitis, kidney injury, gallbladder disease and hypoglycaemia with insulin. It carries an FDA boxed warning for thyroid C-cell tumours.
Key Takeaways
- Semaglutide carries a boxed warning for thyroid C-cell tumours, contraindicated if personal or family history of medullary thyroid carcinoma or MEN2.
- Most common side effects: nausea, vomiting, diarrhoea, constipation, abdominal pain. Worst during initiation and dose escalation.
- Major label warnings: pancreatitis, acute kidney injury, gallbladder disease, hypoglycaemia with insulin/sulfonylureas, hypersensitivity, diabetic retinopathy worsening.
- At Wegovy doses there is an additional warning for suicidal behaviour and ideation, monitor mood.
- Disclose semaglutide use to your anaesthetist before any procedure due to delayed gastric emptying and aspiration risk.
- Check semaglutide against your full medication list with the Allmeds drug interaction checker.
What is Semaglutide, and what is it used for?
Semaglutide is a GLP-1 receptor agonist available as once-weekly injection (Ozempic, Wegovy) or daily oral tablet (Rybelsus).
| Property | Detail |
|---|---|
| Drug name | Semaglutide |
| Brand names | Ozempic, Wegovy, Rybelsus |
| Drug class | GLP-1 receptor agonist |
| FDA approval status | Approved, type 2 diabetes, chronic weight management, CV risk reduction in select populations |
| Route | Subcutaneous injection (Ozempic, Wegovy); oral tablet (Rybelsus) |
| Boxed warning | Thyroid C-cell tumours (animal data) |
| Common GI side effects | Nausea, vomiting, diarrhoea, constipation, abdominal pain |
| Major label warnings | Pancreatitis, kidney injury, gallbladder disease, hypoglycaemia, retinopathy |
What are the side effects of Semaglutide?
The FDA prescribing information for Semaglutide groups side effects into common gastrointestinal symptoms (very frequent at initiation and dose escalation) and serious warnings (less frequent but clinically important). The table below summarises the labelled categories with severity colour-coding.
| Side Effect Category | What May Occur | Why It Matters |
|---|---|---|
| Pancreatitis | Severe, persistent abdominal pain (sometimes radiating to the back), nausea, vomiting | All GLP-1 labels warn about acute pancreatitis. Stop the medicine and seek urgent assessment. |
| Thyroid C-cell tumours (boxed warning) | Neck mass, hoarseness, difficulty swallowing, persistent neck pain | Animal studies show medullary thyroid carcinoma risk. Contraindicated if personal or family history of MTC or MEN2. |
| Acute kidney injury | Reduced urine output, swelling, fatigue, usually after vomiting or diarrhoea | Dehydration from GI side effects can precipitate AKI, particularly in patients with prior renal disease. |
| Severe hypoglycaemia | Sweating, shakiness, confusion, palpitations, seizure, loss of consciousness | Risk rises sharply when combined with insulin or sulfonylureas. Dose reduction of the other glucose-lowering drug is usually required. |
| Gallbladder disease | Right-upper abdominal pain, fever, jaundice | Cholelithiasis and cholecystitis are reported, especially with rapid weight loss. |
| Severe gastrointestinal reactions | Persistent nausea, vomiting, diarrhoea, constipation, abdominal pain | Common and dose-dependent. Most pronounced during initiation and dose escalation. |
| Diabetic retinopathy worsening | Blurred vision, vision changes | Rapid glucose lowering has been associated with transient worsening, relevant in long-standing type 2 diabetes. |
| Hypersensitivity reactions | Rash, urticaria, angioedema, anaphylaxis | Stop the medicine and seek urgent care for serious allergic features. |
| Injection-site reactions | Redness, swelling, itching, induration at the injection site | Usually mild; persistent reactions warrant clinical review. |
| Aspiration risk during anaesthesia | Delayed gastric emptying may leave food in the stomach during sedation | Disclose GLP-1 use to your anaesthetist before any procedure or surgery. |
Taking Semaglutide alongside other medications?
Check Semaglutide against your full medication list instantly. Allmeds scans the widest drug interaction database in minutes.
How does Semaglutide work, and why does that drive the side effects?
Semaglutide is a long-acting GLP-1 receptor agonist. It stimulates glucose-dependent insulin release, suppresses glucagon, slows gastric emptying, and reduces appetite. The mechanism explains both the therapeutic effect and the dominant GI side-effect pattern.
Can you drink alcohol while taking Semaglutide?
Alcohol is not contraindicated but can worsen nausea, dehydration, and hypoglycaemia in those on insulin or sulfonylureas.
Symptoms and when to seek care
Seek urgent medical assessment if you experience any of the following while taking Semaglutide:
- Severe, persistent abdominal pain (possible pancreatitis)
- Sudden swelling of the face, lips, tongue or throat, or difficulty breathing (allergic reaction)
- Right-upper abdominal pain with fever or jaundice (gallbladder disease)
- Severe vomiting or diarrhoea with reduced urine output (dehydration / kidney injury)
- Severe hypoglycaemia, sweating, confusion, palpitations, loss of consciousness (especially if also on insulin or sulfonylurea)
- New neck mass, hoarseness, or difficulty swallowing (thyroid concern)
- New or worsening depression, mood changes, or suicidal thoughts (Wegovy/Zepbound)
Common Questions About Semaglutide Side Effects
Nausea, vomiting, diarrhoea, constipation, abdominal pain, gastrointestinal symptoms dominate the side-effect profile. Most are mild to moderate and worst at initiation and dose escalation.
Both are semaglutide with the same boxed warning and similar major risks. Oral Rybelsus has slightly different GI tolerability and requires strict dosing on an empty stomach. The serious warnings apply equally.
Thyroid C-cell tumours, based on rodent studies. Contraindicated in patients with personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN2).
Yes, acute pancreatitis is a labelled risk. Stop the medicine and seek urgent assessment for severe, persistent abdominal pain that may radiate to the back, especially with vomiting.
Discuss with your prescriber and anaesthetist. Semaglutide slows gastric emptying, which can leave food in the stomach during sedation and create aspiration risk. Many anaesthetic services now pause GLP-1 medicines before elective procedures.
References
- U.S. Food & Drug Administration. Ozempic (semaglutide) prescribing information. fda.gov.
- U.S. Food & Drug Administration. Wegovy (semaglutide) prescribing information. fda.gov.
- U.S. Food & Drug Administration. Mounjaro (tirzepatide) prescribing information. fda.gov.
- U.S. Food & Drug Administration. Zepbound (tirzepatide) prescribing information. fda.gov.
- European Medicines Agency. Ozempic, Wegovy, Mounjaro, EPAR product information. ema.europa.eu.
- Therapeutic Goods Administration (Australia). Australian Register of Therapeutic Goods (ARTG). tga.gov.au.
- Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205–216.
- Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989–1002.
Check Semaglutide against your full medication list
Allmeds AI Pharmacist scans interactions, schedules, and risk flags across your entire medication profile, in minutes.